Value-based Modifier

The Value-based Modifier (VBM) program allows for different reimbursement rates to providers under the Medicare Physician Fee Schedule based on the quality of care furnished at his or her practice, compared to the cost of care during a given reporting period. With quality measures from the PQRS program and claims data on Medicare patients, CMS is tracking providers across the country to create national benchmarks. Depending on how your practice stacks up against the national benchmark, it could be penalized or rewarded up to 4% on their Medicare Part B reimbursements.

This program will have a far-reaching impact as we shift from fee-for-service to value-based payments for physicians.

Moreover, commercial payers are beginning to phase in the same methodology for reimbursement. To see how your practice may be affected by the Value-based Modifier based on the 2016 year of care, see the graphic below.

VBM 2018 (2016 Year of Care)

Contact Miraca Life Sciences to learn how Miraca can assist your practice.
Call 1.855.347.7284 or email EHRPath@MiracaLS.com

If I have any questions, the Miraca dermatopathologists are easily accessible via a quick email or phone call.
— Josephine Chu McAllister, MD,
Dermatologist/Founder, Dermatology Associates of Ithaca, Ithaca, N.Y.


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


May 22, 2017

Miraca Life Sciences Again Expands Therapeutic Drug Monitoring with Addition of First Biosimilar Inflectra®

IRVING, Texas, May 23, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, has further expanded its InformTx™ therapeutic drug monitoring (TDM) capabilities with the addition of testing for Inflectra® (infliximab-dyyb), which is the first biosimilar drug in the test offering. Since launching InformTx in June 2016, Miraca Life Sciences has expanded the service from four to […]

Continue reading


April 18, 2017

Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

Pathologists at Miraca Life Sciences contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Miraca Life Sciences participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Miraca, participation in the Philips study was a project of Miraca […]

Continue reading


April 11, 2017

Ten Research Projects from Miraca Life Sciences Accepted for DDW Conference

IRVING, Texas, April 12, 2017 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Digestive Disease Week® conference (DDW), which will be held May 6–9 in Chicago. DDW is the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, […]

Continue reading


March 27, 2017

Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

IRVING, Texas, March 28, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Miraca Life Sciences now performs TDM […]

Continue reading


November 30, 2016

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since […]

Continue reading